Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Analyst Color

Analyst Color

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Price Target
  • Reiteration
  • Small Cap

Why This ChemoCentryx Analyst Is Bullish

By Nikhil Dayal
Today, 12:22 PM
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a  Buy rating on shares of ChemoCentryx, Inc. with a $28 price target. 

CCXI

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Initiation
  • Price Target
  • Small Cap

Why Zeta Global’s Proprietary Customer Database Has BofA Bullish

By Nikhil Dayal
Today, 12:22 PM
A differentiated proprietary customer database has turned a BofA Securities analyst bullish on shares of Zeta Global Corp (NYSE: ZETA). The Zeta Analyst: Koji Ikeda initiated coverage on shares of Zeta Global Corp. with a Buy rating and $12 price target. 

ZETA

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Initiation
  • Price Target

Why This Hims Analyst Sees Strong Growth Potential In Highly Competitive Market

By Nikhil Dayal
Today, 12:22 PM
The potential for expansion coupled with a highly competitive pharmacy market has a BofA Securities analyst sidelined on shares of Hims & Hers Health, Inc. (NYSE: HIMS).

HIMS

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Price Target
  • Upgrades

American Express Gets Upgrade, ‘Meaningful Upside’ Says Goldman Sachs Analyst

By Priya Nigam
Today, 12:22 PM
While American Express Company (NYSE: AXP) projects reaching its original goals set for 2020 in 2022, the company seems well-positioned to exceed these expectations, according to Goldman Sachs.

AXP

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Price Target
  • Reiteration
  • Tech

Why This Apple Stock Analyst Says It’s Time To Buy

By Shanthi Rexaline
Today, 12:22 PM
After a not-so-enterprising first-half, Apple, Inc.

AAPL

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Price Target
  • Reiteration

BofA Raises XPeng Target On P7, G3i, P5 Prospects

By Priya Nigam
Today, 12:22 PM
While Xpeng Inc - ADR (NYSE: XPEV) is facing strong demand for P7, the G3i launch scheduled for Friday could be the next catalyst, according to BofA Securities.

XPEV

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Media
  • News
  • Retail Sales

Nio Expected To Gross 5% More EV Deliveries In 2021 Than Previous Forecast, Says CICC

By Rachit Vats
Today, 12:22 PM
China International Capital Corporation Limited has updated its forecast for Nio Inc (NYSE: NIO), saying it expects the  Chinese electric vehicle maker to sell 98,000 cars in 2021, 5% more than its previous estimate, as per a cnEVpost

LI

Read More
2 minute read
  • Analyst Color
  • Econ #s
  • Economics
  • News
  • Top Stories

Why The Tight US Labor Market May Be Here To Stay

By Wayne Duggan
Today, 12:22 PM
In a series of blog posts last week, Commonwealth Financial Network chief investment officer Brad McMillan discussed just what’s going on with labor shortages in the U.S. economy.

SPY

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings

Tesla Q2 Deliveries Evidence of ‘True Growth Story,’ EV Maker On Track to Exceed 2021 Deliveries Forecast: Gene Munster

By Shanthi Rexaline
Today, 12:22 PM
Tesla, Inc. (NASDAQ: TSLA) 

GM

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Penny Stocks
  • Price Target
  • Reiteration

Iterum Therapeutics Analyst Remains Bullish Despite Concerns Over FDA Letter

By Nikhil Dayal
Today, 12:22 PM
A lack of clarity and final decision in the U.S. Food and Drug Administration's (FDA) recent letter to Iterum Therapeutics PLC (NASDAQ: ITRM) failed to deter H.C. Wainwright & Co’s bullish sentiment on Iterum stock.

ITRM

Posts navigation

Previous 1 … 477 478 479 … 494 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service